<DOC>
	<DOC>NCT01613482</DOC>
	<brief_summary>Evaluate the survival without metastasis in patients treated by Trastuzumab in association with other chemotherapies for a breast cancer expressing HER2-NEU.</brief_summary>
	<brief_title>TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients with breast cancer, expressing HER2NEU (score +++ in ICH or ++ and amplification on FISH or CISH, SISH) Visceral metastasis, only or multiple First line metastasis treatment by Trastuzumab in association with chemotherapy Good general conditions: OMS=&lt;2 or Karnofsky &gt;=70% Age &gt; 18 years and &lt; 70 years Life expectancy &gt;=3 mois No Trastuzumab since more of 6 months No cerebral metastasis (MRI) Efficacy contraception for women with genital capacities Consent signed by the patient Exclusion Criteria Contraindication to IRM Psychiatric decease Prior cerebral radiotherapy, Geographical constraint, compromising the fallow of patients Infectious or other serious pathology, likely to stop the treatment Positive serology (HIV, hBC, hBS) Inclusion in an other clinical trial or in the 4 weeks before th inclusion Pregnant or breastfeeding women</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>